(19)
(11) EP 3 625 368 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
14.12.2022 Bulletin 2022/50

(45) Mention of the grant of the patent:
09.11.2022 Bulletin 2022/45

(21) Application number: 19765344.7

(22) Date of filing: 08.08.2019
(51) International Patent Classification (IPC): 
C12Q 1/6883(2018.01)
(52) Cooperative Patent Classification (CPC):
C12Q 1/6883; C12Q 2600/156; Y02A 50/30
(86) International application number:
PCT/US2019/045721
(87) International publication number:
WO 2020/033700 (13.02.2020 Gazette 2020/07)

(54)

METHODS FOR ASSESSING THE RISK OF DEVELOPING PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY CAUSED BY JOHN CUNNINGHAM VIRUS BY GENETIC TESTING

VERFAHREN ZUR BEURTEILUNG DES RISIKOS DER ENTWICKLUNG VON DURCH JOHN-CUNNINGHAM-VIRUS VERURSACHTER PROGRESSIVER MULTIFOKALER LEUKENZEPHALOPATHIE DURCH GENETISCHES TESTEN

PROCÉDÉS POUR ÉVALUER LE RISQUE DE DÉVELOPPER UNE LEUCOENCÉPHALOPATHIE MULTIFOCALE PROGRESSIVE PROVOQUÉE PAR LE VIRUS DE JOHN CUNNINGHAM PAR DES PROCÉDÉS DE TEST GÉNÉTIQUE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 08.08.2018 US 201862716072 P
08.08.2018 US 201862716183 P

(43) Date of publication of application:
25.03.2020 Bulletin 2020/13

(60) Divisional application:
22199371.0

(73) Proprietors:
  • PML Screening, LLC
    Newport Beach, CA 92660 (US)
  • Université Paris-Saclay
    91190 Gif sur Yvette (FR)
  • The Assistance Publique-Hôpitaux de Paris (APHP)
    75015 Paris (FR)
  • The Institut National de la Santé et de la Recherche Médicale (INSERM)
    75654 Paris Cedex 13 (FR)

(72) Inventors:
  • HATCHWELL, Eli
    New York, NY 10036 (US)
  • EIS, Peggy S.
    New York, NY 10036 (US)
  • SMITH, Edward B., III
    New York, NY 10036 (US)
  • TAOUFIK, Yassine
    75014 Paris (FR)

(74) Representative: Patent Boutique LLP 
10A Printing House Yard Hackney Road
London E2 7PR
London E2 7PR (GB)


(56) References cited: : 
WO-A2-2018/158632
 US-A1- 2017 016 919
   
  • ELIZABETH A. MILLS ET AL: "Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird's Eye View", FRONTIERS IN IMMUNOLOGY, vol. 9, 2 February 2018 (2018-02-02), XP055647863, DOI: 10.3389/fimmu.2018.00138
  • GUERINI ET AL: "Analysis of CCR5, CCR2, SDF1 and RANTES gene polymorphisms in subjects with HIV-related PML and not determined leukoencephalopathy", BIOMEDICINE AND PHARMACOTHERAPY, ELSEVIER, FR, vol. 62, no. 1, 22 May 2007 (2007-05-22), pages 26-30, XP022418147, ISSN: 0753-3322, DOI: 10.1016/J.BIOPHA.2007.04.005
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).